T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 19% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: donorcelltransplantgreater thantransplantation
  Phrases that lowered it: lymphomahodgkinto evaluatepatients wholeukemia
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 14.1% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 28.2% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 96.9% (raises risk) · Drug's FDA history
• Minimum age: not given (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drugs with FDA adverse-event history: 8 (raises risk) · Drug's FDA history
• Maximum age: 21 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports before start: 68995 (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation NCT02259348 · started 2014 · scored riskier than 94% of active trials terminated
• Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy NCT01807611 · started 2013 · scored riskier than 96% of active trials completed
• Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells NCT01050764 · started 2009 · scored riskier than 93% of active trials terminated
• Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT NCT02988466 · started 2017 · scored riskier than 99% of active trials completed
• Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen NCT02199041 · started 2014 · scored riskier than 86% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.